The fertility drug developer has now secured $20.9m after welcoming Novo to its investor base.

US-based biopharmaceutical company Nora Therapeutics has raised $18m in series B funding from participants including Denmark-based healthcare company Novo.

Nora Therapeutics specialises in the development of reproductive medicine, and the investment is to be used to advance the trials for its NT100 drug. Participants in the round included previous investors Prospect Venture Partners, Rho Ventures, Vivo Capital, Burrill & Company and Heath Lukatch.

NT100 is intended to prevent recurrent infertility and pregnancy loss. The Phase 2 drug trials hope to…